Beyond Air Inc. released its financial results for the fiscal year ending March 31, 2025. The company reported a significant increase in revenue, reaching $3.7 million compared to $1.2 million for the previous year. However, the company also reported a net loss of $48.5 million, slightly improved from the $64.3 million loss in the prior year. Operating expenses were reduced to $42.9 million from $61.7 million, driven by lower research and development and selling, general, and administrative costs. The company, a commercial-stage medical device and biopharmaceutical entity, continues to face challenges reflected in its comprehensive loss, which stood at $46.7 million, compared to $60.3 million in the previous year. No specific outlook or guidance was provided in the report.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。